Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Gilead

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Gilead Boosts 2022 Guidance On The Back Of Its Covid Treatment

Gilead now expects $2.5 billion from its Covid treatment, Veklury, vs. prior views for $2 billion. And GILD stock rocketed Wednesday.

Investors Business Daily

The GOP's "Gilead Playbook"

We're now living in the aftermath of all that the Trump years unleashed. How do we escape this misogynist madness?

Salon

From analysis to the latest developments in health,
read the most diverse news in one place.

Recap Of Friday's Biotech Catalysts - End Of The Day Summary

Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and relatlimab) for treatment of patients with Unresectable or Metastatic Melanoma based on results from the Phase 2/3 RELATIVITY-047 trial. Bristol Myers shares traded in a range of $72.48 to $73.61 on a…

Benzinga

Margaret Atwood defends ‘I told you so’ mug likening post-Roe America to Handmaid’s Tale

‘The Handmaid’s Tale’ imagines a future in which the US has become a fundamentalist, authoritarian, theocratic regime known as Gilead

The Independent UK

As drugmakers cut off discounts, providers fret for low-income patients

Hospitals and community and rural health clinics that serve low-income patients say drug manufacturers have threatened their financial stability by dramatically cutting back their participation in a federal drug discount program that saves those health providers millions of dollars a year.

Tribune News Service

Gilead Again Seeks HIV Drug Approval From FDA After Addressing Vial Compatibility Issues

Gilead Sciences (NASDAQ: GILD) resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Traders See Bumpy Road Ahead For Gilead Sciences

Gilead Sciences, Inc. (NASDAQ: GILD) climbed on Wednesday, even as the S&P 500 ended the day with losses.

Benzinga

Why Gilead Is Cheapest Large-Cap Biotech Despite Some Not So Favorable Acquisitions

Even after spending over $40 billion in the past five years on acquisitions, none of the deals for Gilead Sciences Inc (NASDAQ: GILD) has delivered the blockbuster in cancer as it looked to venture away from the HIV franchise.

Benzinga

Fiction about abortion confronts the complicated history of gender, sexuality and women’s rights

Recent debates around Roe v. Wade in the United States have sparked new conversations about the right to abortion and what it means.

The Conversation

Devastated woman diagnosed with cancer when she was six months pregnant - and now it's incurable

Louise Swain-Hughes, 34, was diagnosed with cancer when she was six months pregnant and is now campaigning for a life-extending drug to be made available on NHS so she can spend more precious time with her son.

Daily Record

Arcus Posts Encouraging Data For Domvanalimab-Based Regimes In Lung Cancer Settings

Arcus Biosciences Inc (NYSE:RCUS) announced results from the third interim analysis of the ongoing Phase 2 ARC-7 study of zimberelimab vs. domvanalimab plus zimberelimab (doublet) vs. domvanalimab plus zimberelimab and etrumadenant (triplet) as a first-line treatment for metastatic non-small cell lung cancer. In this interim analysis, both domvanalimab-containing arms continued to show meaningful…

Benzinga

Why These Analysts Are Bullish On Gilead's Q1 Earnings

RBC Capital Market views Gilead Sciences Inc's (NASDAQ:GILD) Q1 as a solid quarter, with a bottom-line beat reflecting Veklury cash flow boost, solid core business performance despite seasonal headwinds, and in-line operating expenses. The analyst notes that the story remains somewhat catalyst light, especially with transformative M&A likely off the table. HIV sales,…

Benzinga

Gilead Sciences Q1 Results Surpass Street Expectation, FY22 Outlook Midpoint Trails Consensus

Gilead Sciences, Inc. (NASDAQ: GILD) reported firs

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Gilead Sciences Crushes First-Quarter Views As Covid Drug Adds $1.5 Billion

Gilead beat first-quarter estimates on Thursday, though offered a profit view that was a penny light at the midpoint, and GILD stock fell.

Benzinga

Gilead's Remdesivir Becomes First Approved Treatment For Pediatric COVID-19 Patients

The FDA has approved Gilead Sciences Inc's (NASDAQ:GILD) supplemental marketing application for Veklury (remdesivir) for pediatric COVID-19 patients older than 28 days. The approval covers patients weighing at least 3 kg and are either hospitalized with COVID-19 or have mild-to-moderate COVID-19 and are considered high risk for progression to severe infection. This approval…

Benzinga

The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

FDA Lifts Partial Clinical Hold On Gilead's MDS, AML Magrolimab Studies

The FDA has

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

4 Best High-Yield Stocks on the S&P 500: Phillips 66, Gilead, Valero, and Walgreen Boots

The stock market has been experiencing high volatility due to surging inflation, the Ukraine-Russia war, and multiple interest rate increases planned by the Fed this year. So, investors looking to side-step the market’s volatility could be well served by betting on high dividend-yielding stocks. Gilead Sciences (GILD), Walgreens Boots Alliance…

Benzinga

Gilead Sciences' Trodelvy Study In Breast Cancer Meets Primary Endpoint

Gilead Sciences Inc (NASDAQ: GILD) announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer.

Investors Business Daily

Gilead Sciences Dives As Investors Question Its Latest Cancer Buyout

Gilead unveiled mixed results for its drug Trodelvy in women with breast cancer on Monday — and GILD stock sank at the close.

Benzinga

Gilead Hit By FDA Complete Response Letter For Lenacapavir In HIV Infection

The FDA has issued a complete response letter (CRL) for Gilead Sciences Inc's (NASDAQ:GILD) application for lenacapavir for heavily treated multi-drug resistant (MDR) HIV-1 infection. Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor. In the CRL, the FDA has cited Chemistry Manufacturing and Controls (CMC) issues relating to the compatibility of lenacapavir with the…

Investors Business Daily

How To Buy This High-Dividend Stock For A 5% Discount

If Gilead stock stays above 60 at expiry, the put expires worthless leaving the trader with a 36% annualized return.

Benzinga

Gilead's Lenacapavir Shows Sustained Efficacy In Pretreated HIV Patients

Gilead Sciences Inc (NASDAQ: GILD)

Benzinga

Hookipa Pharma Stock Surges On HIV Pact With Gilead

Hookipa Pharma Inc (NASDAQ: HOOK)

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.